Abstract P5-09-16: Real world experience with Carboplatin plus Nab-paclitaxel as neoadjuvant therapy in patients with early triple negative breast cancer
Manuel Alva Bianchi(Research Institute Hospital 12 de Octubre), Eva Ciruelos, Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Lucía Parrilla, Coral García de Quevedo, Pablo Tolosa(Research Institute Hospital 12 de Octubre), Ainhoa Madariaga(Hospital Universitario 12 De Octubre), Cristina González, Laura Lema(Hospital Universitario 12 De Octubre), C. Gonzalez Deza(Hospital Universitario 12 De Octubre), Mario Gonzalez, Oscar A. Campos(University of California, Los Angeles), Luís Manso(Research Institute Hospital 12 de Octubre)
Cited by 0
Related Papers
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
|Annals of Oncology|2021|799
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
|The Lancet|2023|225